Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy

BMC Cancer

卷:20

Thorsten Derlin¹  Matthias Eiber²  Peter Bartenstein³  Christian la Fougère⁴  Irene A. Burger⁵  Michael Mix⁶  Marco M. E. Vogel⁷  Stephanie E. Combs⁷  Nina-Sophie Schmidt-Hegemann⁸  Claus Belka⁸  Jessica Becker⁹  Arndt-Christian Müller⁹  Matthias Guckenberger¹⁰  Stephanie G. C. Kroeze¹⁰  Simon Kirste¹¹  Anca-Ligia Grosu¹¹  Ann-Kathrin Oehus¹²  Hans Christiansen¹²  Christoph Henkenberens¹² 

[1] Department of Nuclear Medicine, Hannover Medical School;

[2] Department of Nuclear Medicine, Technical University Munich;

[3] Department of Nuclear Medicine, University Hospital LMU Munich;

[4] Department of Nuclear Medicine, University Hospital Tübingen;

[5] Department of Nuclear Medicine, University Hospital Zürich;

[6] Department of Nuclear Medicine, University of Freiburg;

[7] Department of Radiation Oncology, Technical University Munich;

[8] Department of Radiation Oncology, University Hospital LMU Munich;

[9] Department of Radiation Oncology, University Hospital Tübingen;

[10] Department of Radiation Oncology, University Hospital Zürich, University of Zurich;

[11] Department of Radiation Oncology, University of Freiburg;

[12] Department of Radiotherapy and Special Oncology, Hannover Medical School;

关键词: PSMA;    Radiotherapy;    Prostate cancer;    Oligometastases;    Recurrence;    Radical prostatectomy;   

DOI  :  10.1186/s12885-020-06883-5

来源: DOAJ

【 摘 要 】

Abstract Background A substantial number of patients will develop further biochemical progression after radical prostatectomy (RP) and salvage radiotherapy (sRT). Recently published data using prostate-specific membrane antigen ligand positron emission tomography (PSMA - PET) for re-staging suggest that those recurrences are often located outside the prostate fossa and most of the patients have a limited number of metastases, making them amenable to metastasis-directed treatment (MDT). Methods We analyzed 78 patients with biochemical progression after RP and sRT from a retrospective European multicenter database and assessed the biochemical recurrence-free survival (bRFS; PSA < nadir + 0.2 ng/ml or no PSA decline) as well as the androgen deprivation therapy- free survival (ADT-FS) using Kaplan-Meier curves. Log-rank test and multivariate analysis was performed to determine influencing factors. Results A total of 185 PSMA – PET positive metastases were detected and all lesions were treated with radiotherapy (RT). Concurrent ADT was prescribed in 16.7% (13/78) of patients. The median PSA level before RT was 1.90 ng/mL (range, 0.1–22.1) and decreased statistically significantly to a median PSA nadir level of 0.26 ng/mL (range, 0.0–12.25; p < 0.001). The median PSA level of 0.88 ng/mL (range, 0.0–25.8) at the last follow-up was also statistically significantly lower (p = 0.008) than the median PSA level of 1.9 ng/mL (range, 0.1–22.1) before RT. The median bRFS was 17.0 months (95% CI, 14.2–19.8). After 12 months, 55.3% of patients were free of biochemical progression. Multivariate analyses showed that concurrent ADT was the most important independent factor for bRFS (p = 0.01). The median ADT-FS was not reached and exploratory statistical analyses estimated a median ADT-FS of 34.0 months (95% CI, 16.3–51.7). Multivariate analyses revealed no significant parameters for ADT-FS. Conclusions RT as MDT based on PSMA - PET of all metastases of recurrent prostate cancer after RP and sRT represents a viable treatment option for well-informed and well-selected patients.

【 授权许可】

Unknown